Other formats:
BibTeX
LaTeX
RIS
@article{1876146,
author = {Horská, Kateřina and Rudá, Jana and Skrede, Silje},
article_location = {LONDON},
article_number = {9},
doi = {http://dx.doi.org/10.1016/j.tem.2022.06.005},
keywords = {antipsychotic; metabolic adverse effects; GLP-1 receptor agonist; pro-cognitive; schizophrenia},
language = {eng},
issn = {1043-2760},
journal = {TRENDS IN ENDOCRINOLOGY AND METABOLISM},
title = {GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?},
url = {https://www.sciencedirect.com/science/article/pii/S1043276022001229?via%3Dihub},
volume = {33},
year = {2022}
}
TY - JOUR
ID - 1876146
AU - Horská, Kateřina - Rudá, Jana - Skrede, Silje
PY - 2022
TI - GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
JF - TRENDS IN ENDOCRINOLOGY AND METABOLISM
VL - 33
IS - 9
SP - 628-638
EP - 628-638
PB - ELSEVIER SCIENCE LONDON
SN - 10432760
KW - antipsychotic
KW - metabolic adverse effects
KW - GLP-1 receptor agonist
KW - pro-cognitive
KW - schizophrenia
UR - https://www.sciencedirect.com/science/article/pii/S1043276022001229?via%3Dihub
N2 - Antipsychotics (APDs) represent a core treatment for severe mental disorders (SMEs). Providing symptomatic relief, APDs do not exert therapeutic effects on another clinically significant domain of serious mental disorders, cognitive impair-ment. Moreover, adverse metabolic effects (diabetes, weight gain, dyslipidemia, and increased cardiovascular risk) are common during treatment with APDs. Among pharmacological candidates reversing APD-induced metabolic adverse effects, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs), approved for both diabetes and recently for obesity treatment, stand out due to their favorable effects on peripheral metabolic parameters. Interestingly, GLP-1 RAs are also proposed to have pro-cognitive effects. Particularly in terms of dual therapeutic mechanisms potentially improving both central nervous system (CNS) deficits and metabolic burden, GLP-1 RAs open a new perspective and assume a clinically advantageous position.
ER -
HORSKÁ, Kateřina, Jana RUDÁ and Silje SKREDE. GLP-1 agonists: superior for mind and body in antipsychotic-treated patients? \textit{TRENDS IN ENDOCRINOLOGY AND METABOLISM}. LONDON: ELSEVIER SCIENCE LONDON, 2022, vol.~33, No~9, p.~628-638. ISSN~1043-2760. Available from: https://dx.doi.org/10.1016/j.tem.2022.06.005.
|
